Clinical trials: Escitalopram
Obsessive-Compulsive Disorder
Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)
Objectives: To evaluate tolerability and efficacy of escitalopram treatment in high dose than 20-50 mg/d in out-patients with OCD Type of the study: Open label, prospective study.
- Trial name
- NCT00305500
- Testing
- escitalopram
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Abarbanel Mental Health Center
Major Depression
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the…
- Trial name
- NCT02237937
- Testing
- Paroxetine, Sertraline, Citalopram
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HolsboerMaschmeyer NeuroChemie GmbH
Obsessive Compulsive Disorder
Predicting Medication Response in Obsessive Compulsive Disorder
In this study, the investigators hope to study a number of variables the investigators believe may help us predict why some people respond better to some medications than others.
- Trial name
- NCT01404871
- Testing
- clomipramine, escitalopram, duloxetine
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- Sunnybrook Health Sciences Centre
Major Depressive Disorder, Depression, Unipolar
A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression
Antidepressants is the primary treatment for depression, but only less than 50% of the patients get clinical remission. There is no objective markers to select antidepressants for clinical treatment .
- Trial name
- NCT03623711
- Testing
- Escitalopram, Duloxetine, Bupropion
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Yuqi Cheng
Major Depressive Disorder
The Efficacy and Cerebral Mechanism of Intradermal Acupuncture for Major Depressive Disorder
Major depressive disorder (MDD) is highly prevalent, affecting nearly 4% of the global population. Pharmacotherapy is the frontline treatment recommended by the guideline, but it also has some limitations such as delayed onset…
- Trial name
- NCT05720637
- Testing
- SSRI, SIA, AIA
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Xiaomei Shao
Sleep Initiation and Maintenance Disorders, Depression
TRIAD - Treatment of Insomnia and Depression
The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.
- Trial name
- NCT00767624
- Testing
- Antidepressant, Desensitization Therapy for Insomnia, Cognitive Behavioral Therapy for Insomnia
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Stanford University
Polycystic Ovary Syndrome
The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS
Objectives: To investigate the effect of Cipralex versus placebo on stress hormones, glucose metabolism, physical and mental health and quality of life in polycystic ovary syndrome(PCOS). Treatment: 2x20 women for 12 weeks.
- Trial name
- NCT01961180
- Testing
- Cipralex
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Odense University Hospital
Stroke, Ischemic
Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity
The brain is able to change throughout life in response to learning, or injury, or to adapt to changes in the environment, which is known as neuroplasticity.
- Trial name
- NCT04221256
- Testing
- Administration of SSRI escitalopram, Paired Associative stimulation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Burke Medical Research Institute
Depression
Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)
The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried.
- Trial name
- TORDIA (NCT00018902)
- Testing
- Fluoxetine, Venlafaxine, Cognitive Behavioral Therapy (CBT)
- Where
- 6 sites in United States
- Volunteers
- 334 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect…
- Trial name
- NCT02279953
- Testing
- Vortioxetine 10-20 mg, SSRI
- Where
- 17 sites in Estonia, Finland and 3 more
- Volunteers
- 151 people
- Sponsor
- H. Lundbeck A/S
Anxiety Disorders, Sleep Apnea
Wearable Devices to Assess Effects of Central Nervous Medications on Physical Conditions in Patients With Sleep Problems
Generalized anxiety disorder (GAD) and obstructive sleep apnea (OSA) are two common diseases and share similar symptoms such as anxiety, poor attention, and poor sleep quality.
- Trial name
- NCT05300386
- Testing
- Escitalopram
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Depression, Mood Disorders
Functional MRI Before and After Treatment for Depression
The purpose of this study is to help us understand how depression changes brain activity and how this relates to mood, anxiety, and cognitive functions like memory.
- Conditions
- Depression, Mood Disorders, Depressive Disorder
- Trial name
- NCT00896441
- Testing
- Citalopram
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Stanford University
Anxiety Disorders, Generalized Anxiety Disorder
Drug Therapy for Generalized Anxiety Disorder Among the Elderly
This study will determine the efficacy of escitalopram (Lexapro®), an anti-anxiety drug, for generalized anxiety disorder (GAD) and the ways genetics affect response to treatment for GAD in elderly individuals.
- Trial name
- NCT00105586
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder With Psychotic Features
Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms
The purpose of this study is to compare the efficacy and tolerability of Seroquel monotherapy for the treatment of Major Depression with Psychotic features with Seroquel plus Selective Serotonin Reuptake Inhibitor.
- Trial name
- Seroquel (NCT00955474)
- Testing
- Quetiapine, escitalopram, Sertraline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Healthy Volunteer
A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers
This is an exploratory study to evaluate the usefulness of fMRI as a biomarker to characterize the response to three centrally active drugs and placebo.
- Trial name
- NCT01045083
- Testing
- RO4917523, escitalopram, methylphenidate
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
- Trial name
- NCT01715805
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 1,022 people
- Sponsor
- Forest Laboratories
Schizophrenia
Escitalopram in Schizophrenia in OCD- Open Label Study
SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology
- Trial name
- NCT00456937
- Testing
- Escitalopram
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- BeerYaakov Mental Health Center
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Premature (Early) Ejaculation
Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation
This randomized controlled trial evaluated the comparative effectiveness and safety of four pharmacological treatments-Citalopram 20mg, Silodosin 4 mg, Dapoxetine 30 mg on demand, and Dapoxetine 30 mg daily-in men with premature…
- Trial name
- NCT07113145
- Testing
- Oral intake of medication
- Where
- Egypt
- Volunteers
- 450 people
- Sponsor
- Beni-Suef University
Depression
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
- Trial name
- PROTECT (NCT00536172)
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska